Pharmaceuticals

Radiopharmaceuticals Market Forecast 2026–2030 Presenting Long-Term Industry Insights

May 4, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Forecasted Market Size Trajectory Of The Radiopharmaceuticals Market From 2026 To 2030?

The radiopharmaceuticals market size has rapidly expanded in recent years. It is anticipated to grow from $7.3 billion in 2025 to $8.25 billion in 2026, at a compound annual growth rate (CAGR) of 13.0%. The notable growth observed in the historic period can be attributed to several factors including the adoption of nuclear imaging technologies, an increase in cancer diagnosis rates, the steady availability of radioisotopes, the expansion of hospital-based nuclear medicine facilities, and various regulatory approvals for diagnostic agents.

The radiopharmaceuticals market is projected to experience substantial growth over the coming years, reaching $13.68 billion by 2030, driven by a compound annual growth rate (CAGR) of 13.5%. This anticipated expansion throughout the forecast period can be linked to several factors, including the advancement of precision oncology, an increasing need for targeted radiotherapies, the proliferation of diagnostic imaging centers, investments in cyclotron infrastructure, and innovations in isotope production technology. Key trends anticipated during this period encompass the growing application of radiopharmaceuticals in oncology, the development of theranostics, the broader adoption of PET and SPECT imaging, the ongoing creation of targeted radiotherapies, and enhancements to nuclear medicine infrastructure.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3471&type=smp

What Major Factors Are Driving The Radiopharmaceuticals Market Forward?

The rising incidence of cancer and cardiovascular ailments is anticipated to fuel the demand within the radiopharmaceuticals market. Radiopharmaceuticals are gaining prominence as a secure and potent therapeutic choice, surpassing traditional medications. These agents offer radiologists a significant advantage in managing cancer and cardiovascular conditions, primarily due to benefits such as targeted therapy. Globally, cancer stands as the second leading cause of mortality, accounting for approximately 1 in 6 deaths. For example, in April 2024, data from the International Agency for Research on Cancer (IARC), a specialized agency based in France, indicated that in 2022, there were almost 20 million new cancer diagnoses and 9.7 million deaths attributed to cancer worldwide. Projections suggest that by 2040, these figures will climb to an estimated 29.9 million new cases and 15.3 million annual deaths. Consequently, the growing number of cancer and cardiovascular disease cases is poised to significantly boost the need for radiopharmaceuticals in treating these illnesses.

What Segment Categories Shape The Radiopharmaceuticals Market Segment Landscape?

The radiopharmaceuticals market covered in this report is segmented –

1) By Type: Diagnostic, Therapeutic

2) By Application: Oncology, Cardiology, Gastroenterology, Neuroendocrinology, Musculoskeletal, Respiratory, Nephrology, Other Applications

3) By End User: Hospitals And Ambulatory Surgical Centers, Diagnostic Centers, Cancer Research Institutes

Subsegments:

1) By Diagnostic: Positron Emission Tomography (PET) Radiopharmaceuticals, Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals

2) By Therapeutic: Alpha Emitters, Beta Emitters, Brachytherapy

Which Trends Are Impacting The Progress Of The Radiopharmaceuticals Market?

Companies operating in the radiopharmaceuticals market are increasingly forming strategic alliances to accelerate innovation and expand access to advanced diagnostic and therapeutic solutions. These collaborations focus on enhancing radiopharmaceutical development, strengthening regional production capabilities, and supporting the growing demand for precision imaging and targeted therapies. For instance, in June 2023, the University of Pittsburgh Medical Center (UPMC), a US-based hospital system, partnered with PharmaLogic Holdings Corporation to co-develop and manufacture new radiopharmaceuticals at a Pittsburgh facility. The partnership aims to expand patient and clinician access to cutting-edge diagnostic and therapeutic agents that are not currently available in nearby regions. Under the non-exclusive agreement, UPMC and PharmaLogic will translate experimental radiopharmaceuticals into clinically useful medications, supporting broader commercialization and accelerating the adoption of novel nuclear medicine treatments.

Who Are The Companies Operating Across The Radiopharmaceuticals Market Value Chain?

Major companies operating in the radiopharmaceuticals market are Cardinal Health, Curium Pharma, Siemens Healthineers AG, Novartis AG, General Electric Company (GE), IBA Group, Bayer AG, Lantheus Medical Imaging Inc., Bracco Imaging S.p.A., Eckert & Ziegler, Nihon Medi-Physics Co. Ltd., Fujifilm Corporation, ANSTO, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Bracco Imaging SpA., Canon Inc., China Isotope & Radiation Corporation (CIRC), Alliance Medical, Advanced Accelerator Applications, JSC Isotope, Pharm-Sintez, Synektik SA, Polatom, RadioMedic sro, ÚJV Rež, Actinium Pharmaceuticals Inc., Alseres Pharmaceuticals Inc., Avid Radiopharmaceuticals, Fusion Pharmaceuticals, Peregrine Pharmaceuticals Inc., PETNET Solutions Inc., Positron Corporation, Triad Isotopes Inc., Telix Pharmaceuticals, Rosatom, Alliance Medical Group, Hologic Inc., Segami Corporation, Eczacýbaþý-Monrol Nuclear Products, NTP Radioisotopes.

Get The Full Radiopharmaceuticals Market Report:

https://www.thebusinessresearchcompany.com/report/radiopharmaceutical-global-market-report

Which Region Holds The Highest Market Share In The Radiopharmaceuticals Market?

North America was the largest region in the global radiopharmaceuticals market in 2025. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the radiopharmaceuticals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Radiopharmaceuticals Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/radiopharmaceutical-global-market-report

Browse Through More Reports Similar to the Global Radiopharmaceuticals Market 2026, By The Business Research Company

Radiotherapy Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/radiotherapy-devices-global-market-report

Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Diagnostic Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/diagnostic-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795